QUANTOSE® IR is a laboratory-developed test (LDT) that assesses insulin resistance. Clinical intervention at the earliest stage of prediabetes could help delay or prevent the onset of type 2 diabetes and other related chronic conditions. Quantose IR is currently available to clinicians in the U.S. and Mexico.
Quantose® IR is based on insulin and three non-glycemic biomarkers. It is the first and only LDT developed and clinically validated using the gold standard for insulin sensitivity, the hyperinsulinemic euglycemic clamp. Our test combines accuracy with the convenience of HOMA-IR in a standardized tool for clinical use.
This simple, easy-to-use test requires only a single, fasted blood draw to measure insulin sensitivity, which is the body's ability to efficiently use insulin to bring glucose into the cells. By identifying insulin resistance, Quantose® IR may identify the early stages of the transition toward type 2 diabetes and cardiovascular disease. This can occur years before changes in hemoglobin A1C and fasting plasma glucose are visible. Hemoglobin A1C and fasting plasma glucose measure glycemic status and were not designed to measure insulin resistance.
- Insulin resistance underlies several chronic conditions - type 2 diabetes, cardiovascular disease, hypertension and polycystic ovarian syndrome (PCOS).1
- It is one of the earliest risk signs for the development of type 2 diabetes and cardiovascular disease and is a predictor of disease progression.2
- Insulin Resistance can be present more than 10 years prior to changes in glycemic measures or the development of diabetes.2
- Current approaches diagnose prediabetes/diabetes when 70 to 80% of beta cell function has already been lost.3
- Overweight or obese
- Have risk factors for type 2 diabetes
- Have cardiovascular disease, such as hypertension
- Have a family history of insulin resistance
- Certain ethnicities – African American, Latino, Native Americans, Asian Americans, Pacific Islanders
- Increasing age
- A Quantose® IR Score is generated using a proprietary algorithm that combines quantitative measures of α-hydroxybutyrate (AHB), oleic acid, linoleoyl-glycerophospocholine (LGPC) and insulin.
- α-Hydroxybutyrate (AHB) – an organic acid that may be a marker of fatty acid oxidation and antioxidant glutathione synthesis (oxidative stress)
- Linoleoyl-glycerophosphocholine (LGPC) – a lipid that may be a marker of fatty acid synthesis in the liver and inflammation
- Oleic acid – a free fatty acid that is a marker of lipolysis and total plasma fatty acids
- For patients who test positive for insulin resistance by Quantose® IR and have been placed on weight-loss treatment, follow-up testing may be conducted once the patient’s weight has stabilized – usually six months post-intervention.
- For patients who test negative for insulin resistance by Quantose® IR, but continue to have risk factors associated with the development of type 2 diabetes and cardiovascular disease, testing along with traditional glycemic markers is suggested every 12 to 24 months at the clinician’s discretion.
- Quantose® IR has been clinically developed and validated using the hyperinsulinemic euglycemic clamp, the gold standard for measuring insulin sensitivity. Our test is a practical and convenient assessment of insulin resistance.
- While HOMA-IR provides a simple method for insulin resistance measurement, it is less accurate than Quantose® IR.1 It is not standardized and primarily measures liver insulin resistance when compared to the hyperinsulinemic euglycemic clamp.
- Fasting insulin does not have a defined insulin resistance cutoff, and results vary widely between laboratories.2
Hemoglobin A1C and fasting plasma glucose were not designed to measure insulin resistance; they measure a patient’s glycemic status.